Merck and Moderna are making headlines after their personalized mRNA cancer vaccine entered Phase 3 clinical trials for melanoma. For most people, it is an exciting medical story. For the synovial sarcoma community, it is something more personal than that. What the Vaccine Is mRNA-4157, combined with Merck’s immunotherapy pembrolizumab, works by sequencing a patient’s […]
